Received Mar 6, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | KH9KK | — |
both components mixed and administered were only liquid; inappropriate dose of vaccine administered; This non-serious case was reported by a other health professional and described the occurrence of inappropriate preparation of medication in a patient who received RSVPreF3 adjuvanted (Arexvy) (batch number ZL4R5, expiry date 16-JAN-2027), (batch number 74S5A, expiry date 16-JAN-2027) and (batch number KH9KK, expiry date 16-JAN-2027) for prophylaxis. On 13-FEB-2026, the patient received Arexvy. On 13-FEB-2026, an unknown time after receiving Arexvy, the patient experienced inappropriate preparation of medication (Verbatim: both components mixed and administered were only liquid) and inappropriate dose of vaccine administered (Verbatim: inappropriate dose of vaccine administered). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK Receipt Date: 25-FEB-2026 While giving an adult RSV vaccine, the medical assistant pulled both components and noticed that the component that typically contained powder was liquid. As a result, both components that were mixed and administered were liquid. The vials had been banded, and she verified that she had the correct vials, so she assumed there had been a formulation change. She later realized that the other combinations in the box included a liquid vial and a powder vial.